Tazemetostat plus chemotherapy for SMARCB1-positive nasal cancer
Treatments studied
Part of Ear, nose & throat clinical trials.
This phase 2 trial tests whether adding tazemetostat to standard induction chemotherapy can shrink locally advanced sinonasal cancer that has a specific gene change (SMARCB1/INI-1 loss). It may help patients who cannot have the cancer removed right away, by improving tumor response and control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18+ years old (and weigh at least 40 kg).
- Your biopsy shows locally advanced sinonasal carcinoma that is SMARCB1/INI-1 deficient, and it has not spread to distant organs (M0).
- Your scans show measurable disease, and you’re able to do daily activities with an ECOG score of 0–2.
- If you had prior cancer treatments, any side effects must be mostly gone (to mild level) or stable before starting this study.
- You have enough blood counts, liver, and kidney function for treatment (based on lab tests).
- You can take pills by mouth and have no major medical problems that would make treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the targeted drug becotatug vedotin with chemo can shrink recurrent adenoid cystic sinus tumors that can't be fully removed by surgery. It's for people whose tumors have a specific protein called EGFR.
This Phase 2 study tests a treatment plan that combines immunotherapy with chemotherapy and chemoradiation for advanced squamous cell cancer in the nasal cavity or sinuses. It aims to improve cancer control in people who are newly diagnosed and have not had prior treatment for this cancer.
This trial tests an investigational drug called sacituzumab tirumotecan for a rare and aggressive type of kidney cancer called renal medullary carcinoma (RMC) or a related variant. The drug is designed to target and deliver treatment directly to cancer cells. The study aims to see if it can shrink tumors or slow the disease in people who have already tried other treatments.
This trial tests pembrolizumab (an immune therapy) for locally advanced sinonasal cancer that can still be cured with local treatments. It aims to improve outcomes by helping your immune system better fight the tumor.
This trial tests a combination of an immunotherapy drug (toripalimab) plus chemotherapy before surgery for sinus cancer that has not spread. The goal is to see if this treatment shrinks the tumor so surgery can be more effective.
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
Hear when a new Sinonasal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.